Chemotherapy with Doxorubicin in Progressive Medullary and Thyroid Carcinoma of the Follicular Epithelium

Abstract

Twenty-two patients (mean age 61) with metastasizing, progressive, nonradioiodine-accumulating thyroid carcinoma of the follicular epithelium were treated with doxorubicin between 2000 and 2005. Tumors were histologically classified as follicular in 15 patients (68%) and papillary in 7 patients (32%). In addition, nine patients (mean age 51 years) with medullary thyroid carcinoma were treated with doxorubicin between 1997 and 2005. Treatment consisted of doxorubicin: either 8 cycles of 15 mg/m² weekly or 3 cycles of 60 mg/m² every 3 weeks, repeated once, depending on response and side effects. The effect of therapy was evaluated by radiographic imaging, [¹⁸F] FDG-PET, and bone scans. In patients with papillary or follicular thyroid carcinoma, 5% had a partial regression over 6 months, 42% had stable disease for a median of 7 months (range: 1-22), and 53% had continuous progression established over 5 months (range: 1-11). Three patients died before completing chemotherapy. In patients with medullary thyroid carcinoma, 11% had a partial regression over 6 months followed by stable disease for 3 months, 11% had stable disease over 7 months, and 79% demonstrated progressive disease established over 5 months (range: 2-12). Doxorubicin can be a valid chemotherapy option, especially for advanced or metastatic thyroid carcinoma of the follicular epithelium.

Key words

[¹⁸F] FDG-PET - malignant disease - endocrine tumor - neoplasm - staging

References

• 1 Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, MacIver B, Sherman SI, Tuttle RM. The American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer.  Thyroid. 2006;  16 109-142
• 2 Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.  Eur J Endocrinol. 2006;  154 787-803
• 3 Bockisch A, Brandt-Mainz K, Gorges R, Muller S, Stattaus J, Antoch G. Diagnosis in medullary thyroid cancer with [¹⁸F] FDG-PET and improvement using a combined PET/CT scanner.  Acta Med Austriaca. 2003;  30 22-25
• 4 Brandt-Mainz K, Muller SP, Gorges R, Saller B, Bockisch A. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer.  Eur J Nucl Med. 2000;  27 490-496
• 5 Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Glabbeke M Van, Oosterom AT van, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.  J Natl Cancer Inst. 2000 2;  92 205-216
• 6 Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P. Measurement of clinical and subclinical tumour response using [¹⁸F]-fluorodeoxyglucose and Positron Emissions Tomography: Review and 1999 EORTC Recommendations.  Eur J Cancer. 1999;  35 1773-1782
• 7 Bonadonna G, Monfardini S, Lena M De, Fossati-Bellani F, Beretta G. Phase I and preliminary phase II evaluation of adriamycin.  Cancer Res. 1970;  30 2572-2582
• 8 Gottlieb J, Hill C. Adriamycin therapy in thyroid carcinoma.  Cancer Chemother Rep. 1975;  6 383-396
• 9 Ahuja S, Ernst H. Chemotherapy of thyroid carcinoma.  J Endocrinol Invest. 1987;  10 303-310
• 10 Benker G, Reinwein D. Ergebnisse der Chemotherapie des Schilddrüsen-karzinoms.  Dtsch Med Wochenschr. 1983;  108 403-406
• 11 Husain M, Alsever RN, Lock JP, George WF, Katz FH. Failure of medullary carcinoma of the thyroid to respond to doxorubicin Therapy.  Horm Res. 1978;  9 22-25
• 12 Droz JP, Charbord P, Rougier Ph, Parmentier C. Echec de la chimiotherapie des cancers de la thyroide.  Bull Cancer. 1981;  68 350
• 13 Shimaoka K, Schoenfeld DA, Wys WD De, Creech RH, Conti R De. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma.  Cancer. 19851;  56 2155-2160
• 14 Droz JP, Rougier P, Goddefroy V, Schlumberger M, Gardet P, Parmentier C. Chemotherapy for medullary cancer of the thyroid. Phase II trials with adriamycin and cis-platinum administered as monochemotherapy.  Bull Cancer. 1984;  71 195-199
• 15 Mann K, Möller LC, Bockisch A, Quadbeck B, Schmid KW, Janssen OE. Chemotherapie beim Schilddrüsenkarzinom.  Onkologe. 2005;  11 78-86
• 16 Scherubl H, Raue F, Ziegler R. Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study.  J Cancer Res Clin Oncol. 1990;  116 21-23
• 17 Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.  Eur J Endocrinol. 2006;  154 787-803 , Erratum in: Eur J Endocrinol 2006; 155: 385

Correspondence